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Psychosocial Obstacles to Hepatitis C
Treatment Initiation Among Patients in
Care: A Hitch in the Cascade of Cure
Philip R. Spradling

,1 Yuna Zhong,1 Anne C. Moorman,1 Loralee B. Rupp,2 Mei Lu

,2 Stuart C. Gordon,2,3 Eyasu H. Teshale,1

Mark A. Schmidt,4 Yihe G. Daida,5 and Joseph A. Boscarino6, for the Chronic Hepatitis Cohort Study (CHeCS) Investigators

There are limited data examining the relationship between psychosocial factors and receipt of direct-acting antiviral
(DAA) treatment among patients with hepatitis C in large health care organizations in the United States. We therefore
sought to determine whether such factors were associated with DAA initiation. We analyzed data from an extensive
psychological, behavioral, and social survey (that incorporated several health-related quality of life assessments) coupled
with clinical data from electronic health records of patients with hepatitis C enrolled at four health care organizations
during 2017-2018. Of 2,681 patients invited, 1,051 (39.2%) responded to the survey; of 894 respondents eligible for
analysis, 690 (77.2%) initiated DAAs. Mean follow-up among respondents was 9.2 years. Compared with DAA recipients, nonrecipients had significantly poorer standardized scores for depression, anxiety, and life-related stressors as
well as poorer scores related to physical and mental function. Lower odds of DAA initiation in multivariable analysis
(adjusted by age, race, sex, study site, payment provider, cirrhosis status, comorbidity status, and duration of followup) included Black race (adjusted odds ratio [aOR], 0.59 vs. White race), perceived difficulty getting medical care in
the preceding year (aOR, 0.48 vs. no difficulty), recent injection drug use (aOR, 0.11 vs. none), alcohol use disorder
(aOR, 0.58 vs. no alcohol use disorder), severe depression (aOR, 0.42 vs. no depression), recent homelessness (aOR,
0.36 vs. no homelessness), and recent incarceration (aOR, 0.34 vs. no incarceration). Conclusion: In addition to racial
differences, compared with respondents who initiated DAAs, those who did not were more likely to have several psychological, behavioral, and social impairments. Psychosocial barriers to DAA initiation among patients in care should
also be addressed to reduce hepatitis C-related morbidity and mortality. (Hepatology Communications 2021;5:400-411).

P

ublic health prevention and control of hepatitis C
entails identification of infected persons through
universal testing, followed by linkage to clinical
services and ensuring that persons linked to care receive
and complete effective treatment.(1-5) On an individual
level, eradication of hepatitis C virus (HCV) infection eliminates the possibility of HCV transmission to

others and reduces morbidity and mortality from HCVattributable hepatic and extrahepatic disease among persons who no longer engage in transmission-associated
behaviors.(4) Despite radical improvement in the treatment of HCV infection since the release of secondgeneration direct-acting antiviral (DAA) medications,
uptake of these drugs in many U.S. general health care

Abbreviations: aOR, adjusted odds ratio; AUDIT-C, Alcohol Use Disorders Identif ication Test; CHeCS, Chronic Hepatitis Cohort Study; DAA,
direct-acting antiviral; GAD-7, Generalized Anxiety Disorder-7 scale; HCV, hepatitis C virus; HIV, human immunodef iciency virus; ICD-9-CM,
International Classif ication of Diseases, Ninth Revision, Clinical Modif ication; PHQ8, Patient Health Questionnaire 8 questions; SF-8, Short
Form 8; WPAI, Work Productivity and Activity Impairment Questionnaire.
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systems has been low.(6-8) Investigators have identified
a variety of sociodemographic and clinical factors associated with reduced likelihood of treatment, including younger age, non-White race, Medicaid coverage,
lower annual income, lesser degrees of liver fibrosis, and
ongoing or recent drug/alcohol use or mental health
disorders.(6-11) However, even in settings in which individuals infected with HCV have largely unrestricted
access to DAAs, uptake can be suboptimal and nonsustained.(9,12,13) Under these conditions, studies have
identified patient factors related to reduced uptake, such
as skepticism about treatment effectiveness and tolerability, limited engagement and negative experiences with
providers and health care systems, a lack of perceived
urgency for treatment, and competing situational priorities and demands.(12-15)
Few studies have directly examined, using validated
psychometric instruments, the psychosocial impediments to treatment initiation among identified patients
with hepatitis C who receive integrated clinical care
in large U.S. health care organizations. A recent study
that classified reasons for DAA noninitiation based on
clinical record review found that psychosocial issues
were the principal barriers to hepatitis C treatment in
an urban academic medical practice.(16) In an earlier
study in the pre-DAA era, we found a high degree of
physical and psychological impairment among patients
in our hepatitis C cohort based on responses to a survey that incorporated several quality of life measures
as well as information on employment status, drug/
alcohol/tobacco use, recent psychological stressors, and
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levels of social support.(17) To examine whether these
factors were associated with receipt of treatment in
the DAA era, we repeated this survey during 20172018. Our objective in this analysis was to compare
the psychological, behavioral, and social characteristics
of patients with diagnosed hepatitis C who initiated
DAAs with those who did not initiate DAAs.

Patients and Methods
STUDY POPULATION

We analyzed data collected from adults with chronic
HCV infection in the Chronic Hepatitis Cohort Study
(CHeCS), an observational study of patients who receive
integrated health care services at four sites: Geisinger
Health System in Danville, PA; Henry Ford Health
System in Detroit, MI; Kaiser Permanente Northwest
in Portland, OR; and Kaiser Permanente Hawaii in
Honolulu, HI. The criteria for cohort inclusion and
analytic methods involved in its derivation have been
described in detail.(18,19) The cohort was created based
on analysis of electronic health records and administrative data (supplemented with individual chart review) of
approximately 2.7 million patients aged ≥18 years who
had at least one clinical service visit (i.e., outpatient or
inpatient, emergency department, or laboratory test)
from January 1, 2006, to December 31, 2013. Patients
who met a combination of laboratory-based (i.e., positive HCV RNA) and International Classification
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of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM)-based criteria identifying them as having chronic HCV infection were included.(18) Among
these patients, prospective follow-up data were available through December 31, 2018. The study protocol
was reviewed by an Institutional Review Board and
approved by the Office for Human Research Protections
at each participating study site. The CHeCS investigation follows the guidelines of the U.S. Department of
Health and Human Services regarding the protection
of human subjects. The CHeCS study protocol was
approved and is renewed annually by the institutional
review board at each participating site.

DERIVATION OF THE SURVEYED
COHORT
To determine the patient population available for
survey invitation, we excluded from the CHeCS hepatitis C cohort those who had died, those who had
achieved sustained virologic response (SVR) from any
hepatitis C treatment before 2014, and those without
contact information. All patients prescribed all-oral second-generation DAA regimens after January 1, 2014,
and before survey invitation and had not undergone liver
transplant were invited from March through November
2017 to participate. A sample of CHeCS DAAuntreated chronic hepatitis C intended control patients
with evidence of continuing care in the previous 5 years
(approximately 1:1 untreated to treated at the time of
invitation), matched by sex and 5-year birth year range
at each site, were also invited to participate in the survey.
Patients were sent an invitation letter by U.S. mail at
three of the study sites and through the medical record
portal at one site (Portland, OR). The letter explained
the survey and provided a unique access code for online
completion and offered a $25 incentive for participation.
If no response was received after 6 weeks, telephone
recruiters made up to five attempts to offer the survey as
an in-person interview and to encourage online completion of the survey if an interview was declined.

Hepatology Communications, March 2021

geocode), and study site. Clinical data collected included
HCV genotype, cirrhosis status, Charlson comorbidity score, and duration of CHeCS follow-up. Cirrhosis
was defined according to any of the following criteria:
a) fibrosis-4 score >5.88(20); b) liver biopsy equivalent to
Metavir F4 or transient elastography results >12.5; or c)
ICD-9-CM/ICD-10-CM and Current Procedural
Terminology codes consistent with cirrhosis or hepatic
decompensation (Supporting Material Appendix S1).(21)
Charlson comorbidity scores were calculated from diagnosis codes (excluding liver-related comorbidities) and
were used to categorize patients into scores of 0, 1, or ≥2,
where a score of 0 indicated no listed comorbidities, 1
indicated a single comorbidity, and a score of 2 or higher
indicated multiple comorbidities.(22) Receipt of and start
dates for DAA regimens were confirmed based on individual chart review data for all invited participants.
From the survey, we collected information on
access to health care, smoking history, drug and alcohol use, employment and work productivity, the presence of affective and anxiety disorders, and life events
and social support. Access to health care assessment
included questions about difficulty in getting medical
appointments, the time and mode of travel required to
get to appointments, and the use of the Department
of Veterans Affairs health system for hepatitis C care.
The survey also incorporated several health-related
quality of life instruments, including the Alcohol Use
Disorders Identification Test (AUDIT-C),(23) the Work
Productivity and Activity Impairment Questionnaire
(WPAI),(24) the Patient Health Questionnaire 8
questions (PHQ8) instrument for depression,(25) the
Generalized Anxiety Disorder-7 (GAD-7) scale,(26) a
validated stressful life events scale adapted from Holmes
and Rahe stress scale,(27-28) Short Form 8 (SF-8) physical and mental components,(29,30) and an abbreviated
Medical Outcomes Study Social Support Survey.(31,32)
Details and scoring methods of these instruments can
be found in Supporting Material Appendix S2.

DATA COLLECTED BY
ELECTRONIC HEALTH RECORDS
AND SURVEY

COMPARISONS OF SURVEY
RESPONDENTS VERSUS
NONRESPONDENTS AND OF
RESPONDENTS WHO INITIATED
VERSUS DID NOT INITIATE DAAs

We collected demographic information from electronic health records, including age, sex, race/ethnicity,
mean annual household income (by census tract

Among CHeCS patients with hepatitis C invited to
participate in the survey, we compared survey respondents with nonrespondents according to data derived
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from electronic health records alone, which included
demographics, study site, and clinical characteristics
(HCV genotype, cirrhosis status, Charlson comorbidity score, receipt of DAAs, and duration of CHeCS
follow-up). Among patients who responded to the
survey, we compared characteristics of those who initiated DAA treatment before their survey response date
with those who had not initiated DAAs before their
survey response. We compared characteristics among
respondents with respect to the aforementioned data
from electronic health records as well as surveyderived data elements that pertained to access to health
care, smoking history, drug and alcohol use, employment and work productivity, the presence of affective
and anxiety disorders, and life events and support.
Among respondents who did not initiate DAAs, we
examined responses to survey questions that addressed
access to care issues, including the specialty care referral experience and self-reported reasons for not starting treatment.

STATISTICAL ANALYSIS
Analyses were conducted using SAS 9.4 (Cary, NC).
For univariable analysis, the two-sided chi-square test
and t test were used to compare differences for categorical and continuous variables, respectively; we considered P < 0.05 statistically significant. To examine
factors associated with DAA initiation among survey
respondents, we also conducted multivariable logistic
regression analysis, controlling (selected a priori) for
age, race, sex, study site, insurance status, cirrhosis
status, Charlson comorbidity score, and duration of
follow-up.

Results

STUDY POPULATION AND
DERIVATION OF SURVEYED
COHORT

Of 20,349 patients in the chronic hepatitis C
cohort, 2,361 had achieved SVR before 2014 and
4,103 had died or had no contact information, leaving 13,885 eligible for the survey. Of these, 2,681
were invited during March through November 2017
to participate; invitees included all 1,408 patients
who had been prescribed all-oral second-generation
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DAA regimens in CHeCS on or after January
1, 2014, and before survey invitation and 1,273
intended control patients (i.e., who had not received
DAA before survey invitation), matched by age, sex,
and study site. With the passage of time between
survey invitation and response, however, 410 (32.2%)
of the intended control patients had received DAAs
before their date of response to the survey, leaving in
effect a final survey-invited sample of 1,818 patients
treated with DAA and 863 patients not treated with
DAA (n = 2,681).

COMPARISON OF SURVEY
RESPONDENTS WITH
NONRESPONDENTS
Of these 2,681 patients invited to participate, 1,051
(39.2%) responded to the survey. Compared with survey nonrespondents, respondents were more likely to
be non-Hispanic White, aged 51-70 years, and have
annual income ≥$30,000, Medicaid or Medicare plus
supplemental insurance coverage, and a Charlson
comorbidity score ≥1 (Table 1).

COMPARISON OF SURVEY
RESPONDENTS WHO INITIATED
VERSUS DID NOT INITIATE DAAs
Among the 1,051 patients who responded to the
survey, we excluded 126 respondents with characteristics that could affect the receipt of DAAs: previous clinical trial participation (n = 30), hepatitis B
virus coinfection (n = 16), human immunodeficiency
virus (HIV) coinfection (n = 27), and liver transplant between survey selection and completion date
(n = 62). We excluded an additional 31 patients who
reported DAA receipt on the survey but for whom we
could not confirm a DAA prescription or fill order
from electronic health records. With respect to analysis of characteristics associated with receipt of DAAs,
the final cohort comprised 894 survey respondents,
of whom 690 (77.2%) initiated and 204 (22.8%) did
not initiate DAAs. Among these 894 respondents,
the mean follow-up in the CHeCS was 9.2 years;
patients who did not initiate DAAs had significantly
more follow-up than those who did (11.2 vs. 8.6 years,
P < 0.001).
In the univariable analysis, compared with respondents who received DAAs, those not receiving DAAs
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TABLE 1. DEMOGRAPHICS AND CLINICAL FACTORS OF PATIENTS WITH CHRONIC HEPATITIS C
INVITED TO PARTICIPATE IN THE 2017-2018 SURVEY, ACCORDING TO RESPONSE (CHeCS)
Variables

N (%)

Responded n (%)

Did Not Respond n (%)

P Value

Total

2,681

1,051 (39.2)

1,630 (60.8)

−

Sex
Male

1,614 (60.2)

608 (57.8)

1,006 (61.7)

Female

1,067 (39.8)

443 (42.2)

624 (38.3)

0.048

Race
Non-Hispanic White

1,498 (55.9)

654 (62.2)

844 (51.8)

Non-Hispanic Black

942 (35.1)

311 (29.6)

631 (38.7)

Other

241 (9.0)

86 (8.2)

155 (9.5)

<0.001

Age (years) on Jan 1, 2017
≤30

60 (2.2)

17 (1.6)

43 (2.6)

31-40

106 (4.0)

32 (3.0)

74 (4.5)

41-50

130 (4.8)

45 (4.3)

85 (5.2)

51-60

665 (24.8)

276 (26.3)

389 (23.9)

61-70

1,469 (54.8)

601 (57.2)

868 (53.3)

251 (9.4)

80 (7.6)

171 (10.5)

>70

0.005

Insurance status (6 missing)
None

95 (3.6)

23 (2.2)

72 (4.4)

Private

1,110 (41.5)

385 (36.6)

725 (44.6)

Medicaid

376 (14.1)

175 (16.7)

201 (12.4)

Medicare

911 (34.1)

287 (27.3)

624 (38.4)

Medicare + supplement

183 (6.8)

181 (17.2)

2 (0.1)

<0.001

Annual income (88 missing)
701 (27.0)

245 (24.0)

456 (29.0)

1,065 (41.1)

424 (41.5)

641 (40.8)

827 (31.9)

352 (34.5)

475 (30.2)

Portland, OR

274 (10.2)

141 (13.4)

133 (8.2)

Honolulu, HI

149 (5.6)

70 (6.7)

79 (4.8)

Detroit, MI

1,645 (61.4)

579 (55.1)

1,066 (65.4)

Danville, PA

613 (22.9)

261 (24.8)

352 (21.6)
1,088 (81.3)

<$30K
$30-<50K
≥$50K

0.009

Study Site

<0.001

Genotype (412 missing)
Genotype 1

1,859 (81.9)

771 (82.8)

Genotype 2

199 (8.8)

82 (8.8)

117 (8.7)

Genotype 3

159 (7.0)

59 (6.3)

100 (7.5)

Genotype 4-6

45 (2.0)

16 (1.7)

29 (2.2)

Genotype mixed

7 (0.3)

3 (0.3)

4 (0.3)

Decompensated

321 (12.0)

142 (13.5)

179 (11.0)

Compensated

734 (27.4)

288 (27.4)

446 (27.4)

1,626 (60.6)

621 (59.1)

1,005 (61.7)

0.780

Cirrhosis status

None

0.128

Charlson comorbidity score
0

1,730 (64.5)

639 (60.8)

1,091 (66.9)

1

363 (13.5)

168 (16.0)

195 (12.0)

2+

588 (21.9)

244 (23.2)

344 (21.1)

0.002

9.71 (0.11)

9.62 (0.18)

9.77 (0.14)

0.340

Mean years (SE) CHeCS follow-up

more likely were aged ≤40 and >70 years (marginally, P = 0.049), had Medicaid and Medicare (i.e.,
standard Medicare without a Medicare Advantage
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plan or a supplemental Medigap plan [e.g., Part E,
F]) coverage, had annual income <$50,000, were
affiliated with the Pennsylvania study site, and had
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no cirrhosis. For access to care, substance use, and
quality of life scores, those not receiving DAAs were
more likely to report the following compared with
those who received DAAs: difficulty obtaining medical treatment in the preceding year, dependence on
others (including public transportation) to attend
clinic appointments, current smoking, a history
of drug injection in the preceding 6 months, and
having received substance use disorder treatment.
Patients who did not receive DAAs were also more
likely in the preceding year to have had legal problems, been homeless, and to have been incarcerated.
Compared with DAA recipients, those not receiving
DAAs more likely had AUDIT-C scores consistent
with alcohol use disorder (Table 2), had a higher
mean percentage of time that hepatitis C affected
general activities, had higher (i.e., worse) mean
PHQ8 depression and GAD-7 anxiety scores, had
lower (i.e., worse) mean SF-8 mental and physical
function scores, and had higher mean scores on the
abbreviated Holmes and Rahe stress scale (Table 3).
There were no differences according to sex, HCV
genotype, Charlson comorbidity score, travel time
necessary to access care, history of military service,
employment status, and a noncurrent history of
smoking or drug use.
In the logistic regression analysis adjusted for
age, race, sex, study site, insurance status, cirrhosis
status, Charlson comorbidity score, and duration of
follow-up, characteristics associated with lower odds
of receiving DAAs included non-Hispanic Black
race (adjusted odds ratio [aOR], 0.59 compared
with non-Hispanic White race), affiliation with
the Pennsylvania site (aOR, 0.59 compared to the
Michigan site), difficulty getting medical care in the
preceding year (aOR, 0.48 compared with no difficulty), injection drug use in the preceding 6 months
(aOR, 0.11 compared with no recent injection), positive AUDIT-C score (aOR, 0.58 compared with
negative score), PHQ8 score consistent with severe
depression (aOR, 0.42 compared with no depression), homelessness in the preceding year (aOR, 0.36
compared with not homeless), and incarceration in
the preceding year (aOR, 0.34 compared with no
incarceration) (Table 2). Patients with compensated
cirrhosis had greater odds of receiving DAAs (aOR,
1.77 compared with no cirrhosis).
Among respondents who did not initiate DAAs,
we examined responses to survey questions that
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addressed access to care issues, including the specialty care referral experience and self-reported reasons for not starting treatment. Among those who
had not received specialty care, 34.5% said they were
never referred, 11.9% did not know whether or why
they had not been referred, 10.7% had more pressing medical issues, 8.3% reported they “did not feel
sick,” 6.0% were unable to pay for additional care
visits, 4.8% lacked transportation, and 15.5% had
some “other reason.” Among respondents referred
but not treated, 19.5% reported that the provider
said they were “not sick enough,” 13.3% were not
sure why they were not treated, 11.6% were denied
insurance coverage, 5.2% reported other medical conditions, 4.7% reported cost, 3.3% reported
alcohol or drug use, 2.8% reported more urgent
personal issues, 1.4% were waiting for better treatment options, 0.9% did not want to start DAAs,
0% said they did not start because of a history of
nonadherence, 22.1% said it was for “other reasons.”
(Note: percentages do not add to 100 because blank
responses were not included.)

Discussion

To determine patient characteristics associated
with receipt of DAAs, we examined responses to an
extensive psychosocial survey coupled with electronic
health records of approximately 900 patients with
chronic hepatitis C enrolled in four large health care
organizations in the United States. These patients
had a mean follow-up of approximately 9 years.
Survey-derived data in univariable analysis revealed
that those who did not initiate DAAs were more
likely to report adverse behavioral, psychological,
and social conditions compared with patients who
received treatment. These included perceived difficulties accessing health care providers and dependence on others to get to health care appointments
as well as recent injection drug use, alcohol use disorder, current smoking, higher depression and anxiety scores, homelessness, and legal difficulties and
incarceration. Compared with patients who received
DAAs, those who did not reported significantly
higher levels of stress, more hepatitis C-attributed
impairment of daily activities, lower levels of physical and mental function, and lesser degrees of social
support. Findings were similar in the multivariable

405

SPRADLING ET AL.

Hepatology Communications, March 2021

TABLE 2. CHARACTERISTICS AND SURVEY RESPONSES OF PATIENTS WITH CHRONIC HEPATITIS C
ASSOCIATED WITH INITIATION OF DAAS (CHECS, 2017-2018)
Univariable

Multivariable†

n (%)

DAA Before
Survey n (%)

No DAA Before
Survey n (%)

P Value*

894

690 (77.2)

204 (22.8)

−

Male

508 (56.8)

399 (57.8)

109 (53.4)

0.300

Female

386 (43.2)

291 (42.2)

95 (46.6)

Non-Hispanic White

555 (62.1)

437 (63.3)

118 (57.8)

Non-Hispanic Black

266 (29.8)

193 (28.0)

73 (35.8)

0.59 (0.36-0.98)

0.040

73 (8.2)

60 (8.7)

13 (6.4)

0.82 (0.41-1.65)

0.579

Variables
Total

aOR of DAA Before
Survey (95% CI)

P Value

Sex
ref
1.00 (0.69-1.46)

0.992

Race

Other

0.081

ref

Age (years) on Jan 1, 2017
≤30

16 (1.8)

9 (1.3)

7 (3.4)

31-40

28 (3.1)

16 (2.3)

12 (5.9)

0.049

1.18 (0.33-4.26)

ref
0.801

41-50

38 (4.3)

30 (4.3)

8 (3.9)

3.16 (0.81-12.28)

0.097

51-60

240 (26.8)

187 (27.1)

53 (26.0)

1.90 (0.64-5.61)

0.246

61-70

505 (56.5)

397 (57.5)

108 (52.9)

2.16 (0.73-6.42)

0.166

67 (7.5)

51 (7.4)

16 (7.8)

1.95 (0.53-7.10)

0.312

>70
Insurance status
None

19 (2.1)

12 (1.7)

7 (3.4)

Private

338 (37.8)

280 (40.6)

58 (28.4)

<0.001

1.53 (0.44-5.31)

ref
0.501

Medicaid

154 (17.2)

107 (15.5)

47 (23.0)

0.90 (0.25-3.17)

0.868

Medicare

236 (26.4)

170 (24.6)

66 (32.4)

0.90 (0.26-3.15)

0.873

Medicare + supplement

147 (16.4)

121 (17.5)

26 (12.7)

2.32 (0.61-8.78)

0.216

Annual income (27 missing)
<$30K

212 (24.5)

151 (22.6)

61 (30.7)

≥$30-<50K

359 (41.4)

265 (39.7)

94 (47.2)

<0.001

0.94 (0.60-1.48)

ref
0.785

≥$50K

296 (34.1)

252 (37.7)

44 (22.1)

1.69 (0.98-2.90)

0.057

Portland, OR

130 (14.5)

109 (15.8)

21 (10.3)

Honolulu, HI

62 (6.9)

55 (8.0)

7 (3.4)

Detroit, MI

467 (52.2)

366 (53.0)

101 (49.5)

ref

Danville, PA

235 (26.3)

160 (23.2)

75 (36.8)

0.59 (0.36-0.96)

Study site
<0.001

1.63 (0.80-3.32)

0.179

1.74 (0.72-4.23)

0.222
0.033

Cirrhosis status
79 (8.8)

67 (9.7)

12 (5.9)

1.63 (0.78-3.42)

0.196

Compensated

Decompensated

243 (27.2)

201 (29.1)

42 (20.6)

0.005

1.77 (1.13-2.78)

0.013

None

572 (64.0)

422 (61.2)

150 (73.5)

ref

No

802 (90.2)

634 (92.4)

168 (82.8)

Yes

87 (9.8)

52 (7.6)

35 (17.2)

Drive self

628 (70.8)

505 (73.6)

123 (61.2)

Friend/family member drives

Difficulty getting medical treatment in the past
year (5 missing)
<0.001

ref
0.48 (0.27-0.83)

0.009

Mode of travel to health care provider (7
missing)
0.005

ref

172 (19.4)

118 (17.2)

54 (26.9)

0.63 (0.40-1.02)

0.059

Take public transportation

80 (9.0)

57 (8.3)

23 (11.4)

0.66 (0.35-1.25)

0.206

Walk or ride bicycle

7 (0.8)

6 (0.9)

1 (0.5)

1.32 (0.14-12.29)

0.806

No

424 (58.5)

341 (61.7)

83 (48.3)

Yes

301 (41.5)

212 (38.3)

89 (51.7)

Current smoker

406

0.003

ref
0.68 (0.44-1.03)

0.069
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TABLE 2. Continued
Univariable

Multivariable†

n (%)

DAA Before
Survey n (%)

No DAA Before
Survey n (%)

P Value*

No

412 (97.4)

311 (98.7)

101 (93.5)

0.008

Yes

11 (2.6)

4 (1.3)

7 (6.5)

No

588 (66.3)

474 (69.3)

114 (56.2)

Yes

299 (33.7)

210 (30.7)

89 (43.8)

Negative

696 (79.0)

549 (80.7)

147 (73.1)

Positive

185 (21.0)

131 (19.3)

54 (26.9)

Negative <10

629 (72.8)

501 (75.3)

128 (64.3)

Moderate 10-14

119 (13.8)

88 (13.2)

31 (15.6)

0.72 (0.42-1.24)

0.233

Moderate-severe 15-19

74 (8.6)

50 (7.5)

24 (12.1)

0.71 (0.38-1.33)

0.287

Severe ≥20

42 (4.9)

26 (3.9)

16 (8.0)

0.42 (0.20-0.90)

0.025

No

807 (91.3)

632 (92.4)

175 (87.5)

Yes

77 (8.7)

52 (7.6)

25 (12.5)

No

858 (96.8)

671 (97.8)

187 (93.5)

Yes

28 (3.2)

15 (2.2)

13 (6.5)

No

864 (97.6)

674 (98.3)

190 (95.5)

Yes

21 (2.4)

12 (1.7)

9 (4.5)

Variables

aOR of DAA Before
Survey (95% CI)

P Value

Injected drugs in last 6 months
ref
0.11 (0.02-0.54)

0.006

Ever in drug treatment program (7 missing)
<0.001

ref
0.83 (0.55-1.25)

0.363

AUDIT-C score (13 missing)
0.023

ref
0.58 (0.38-0.90)

0.015

PHQ8 depression score categories (30
missing)
0.007

ref

Legal problems in past year (10 missing)
0.045

ref
0.66 (0.35-1.23)

0.188

Homeless in past year (8 missing)
0.005

ref
0.36 (0.14-0.94)

0.037

Incarcerated in past year (9 missing)
0.033

ref
0.34 (0.12-0.94)

0.037

*Two-sided chi-square test.
†
Multivariable logistic regression analysis adjusted for sex, race, age, insurance status, study site, cirrhosis status, Charlson comorbidity
score, and length of follow-up.
Variables omitted from table for brevity and nonsignificance: time needed to travel, history of military service, planned to use VA for
hepatitis C care, past smoker, injected drugs in the past, used needle exchange in the past, illicit drug use in the past, employment status.
Abbreviations: CI, confidence interval; ref, reference; VA, Veterans Affairs.
TABLE 3. SURVEY RESPONSES OF PATIENTS WITH CHRONIC HEPATITIS C ACCORDING TO RECEIPT OF
DAAS (CHeCS, 2017-2018)
Variables
Total

Mean (SE)

DAA Before Survey,
Mean (SE)

No DAA Before Survey,
Mean (SE)

P Value

894

690 (77.2)

204 (22.8)

−

Mean years of follow-up

9.22 (0.19)

8.63 (0.22)

11.20 (0.37)

<0.001

Mean hours of missed work in the past week due to hepatitis
C (5 missing)

0.57 (0.21)

0.48 (0.20)

0.92 (0.67)

0.410

Mean percentage of the time hepatitis C affected activities

14.69 (1.18)

12.47 (1.26)

21.74 (2.79)

0.002

Mean percentage of the time hepatitis C affected work
productivity

4.73 (0.82)

4.01 (0.85)

7.78 (2.30)

0.091

Mean PHQ8 depression score (30 missing)

6.21 (0.21)

5.79 (0.23)

7.61 (0.49)

<0.001

Mean GAD7 anxiety score in 2017 survey (not included in
2011-2012 survey) (26 missing)

5.62 (0.21)

5.26 (0.23)

6.83 (0.47)

0.003

Mean Stressful Life Events score (34 missing)

0.96 (0.04)

0.91 (0.04)

1.13 (0.09)

0.015

Mean SF-8 mental function score (26 missing)

46.66 (0.39)

47.38 (0.44)

44.23 (0.84)

<0.001

Mean SF-8 physical function score (26 missing)

43.94 (0.39)

44.45 (0.44)

42.20 (0.82)

0.012

Mean social support score (105 missing)

4.00 (0.13)

3.87 (0.15)

4.46 (0.28)

0.042
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model; lower odds of DAA initiation were associated with perceived difficulties getting medical
care, severe depression, alcohol use disorder, and
recent injection drug use, homelessness, or incarceration. Unlike the univariable analysis results, nonHispanic Black race was also associated with lower
odds of DAA initiation in the multivariable model (as
we found in an earlier uptake analysis of our cohort(8)).
Efforts to eliminate hepatitis C hinge foremost on
the identification of infected persons and enabling
their access to clinical care. However, considerable
barriers to DAA initiation, which is a critical stage in
the cascade of care, may remain even when a patient
with identified hepatitis C is “in care.” The steps
needed to initiate DAAs may require a persistence
and commitment that exceeds the capacity of persons
with other more urgent and acute demands and priorities or of those afflicted with comorbid illness. For
example, psychiatric conditions, such as severe depression, may impair one’s ability to engage the medical
system and pursue the often rigorous process of gaining payer approval for DAA treatment. Additional
limitations involving social support, transportation
to appointments, or concurrent problems related to
employment, housing, and legal entanglements, may
further complicate the pursuit of treatment. Multiple
clinic visits for diagnostic assessment and drug testing,
appointments with social workers and patient navigators, and numerous phone calls may be required to
complete the preauthorization process; any of these
might be impracticable or insurmountable for persons
with ongoing psychosocial impairments.
Studies have examined interventions to alleviate
barriers to various components of the hepatitis C care
cascade. Measures to improve treatment initiation, the
focus of this analysis, have included patient education
and outreach, colocalization of services, nonspecialist
hepatitis C treatment education and care delivery, use
of telemedicine, patient navigation programs, and cost
management approaches to help defray out-of-pocket
expenses.(33-36) In recent years, government-affiliated
health care systems, such as in the U.S. Department
of Veterans Affairs, Cherokee Nation, and Alaskan
Native Tribal Health Consortium, have demonstrated
remarkable improvements in DAA access and uptake,
illustrating the potential advantages of unified health
delivery systems with relatively homogeneous patient
populations.(37-40) In the private sector, specialty clinics embedded within large health care organizations
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also have demonstrated the capacity to improve
DAA access. During 2014 through 2017, cumulative
DAA uptake among Kaiser Permanente Northern
California patients with HIV/HCV coinfection was
70%.(41) These patients received health care planning
support from case managers and were prioritized for
hepatitis C treatment, which was coordinated within
each medical facility by a lead infectious disease clinician and a system-wide hepatitis C task force comprised of clinicians, researchers, and community-based
advocates. Improving DAA uptake may be more challenging among a less unified hepatitis C population
(i.e., not otherwise united by a shared clinical condition, such as HIV coinfection) in private sector health
care organizations. For example, during the same
time period, we found that approximately 33% of all
CHeCS patients with active HCV infection initiated
DAAs.(42) However, at the Kaiser Permanente Hawaii
study site, nearly 45% initiated treatment. In 2003,
this site established a dedicated hepatitis C clinic and
began taking a proactive approach to hepatitis C management using a framework to prompt primary care
providers to consider specialty care referral for assessment and treatment of patients infected with HCV
at the time of diagnosis.(43) In contrast, patients with
hepatitis C in more diffuse care networks, particularly
those serving nonurban populations, may have challenges in accessing specialty care and DAAs.(44) This
may in part explain why patients at the Pennsylvania
study site, a network serving a sizable nonurban population, had lower odds of initiating DAAs than those
at the other three sites.
Expanding the pool of health care professionals who
can provide DAAs can also improve treatment uptake.
Data demonstrate that hepatitis C treatment can be
effectively delivered by primary care physicians, nurse
practitioners, clinical pharmacy specialists, physician
assistants, and registered nurses without compromising treatment efficacy or safety.(45,46) Accordingly, the
American Association for the Study of Liver Diseases
Hepatitis C Guidance Panel recently published simplified treatment algorithms for treatment-naive adults
(without cirrhosis or with compensated cirrhosis).(2)
These algorithms are designed to be used by any health
care provider knowledgeable about hepatitis C, including those without extensive experience who have access
to a specialist, and cover guidance on pretreatment
assessment, on-treatment monitoring, assessment of
response, and posttreatment management.
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Although our surveyed population eligible for analysis consisted of approximately 900 respondents with
long-term follow-up, our results may not be generalizable to the entire CHeCS hepatitis C cohort (as
only 40% of invited patients responded), to other geographic settings, or to cohorts with different characteristics. Indeed, our surveyed population could be viewed
as a unique subset of the complete CHeCS hepatitis
C cohort as uptake within the surveyed cohort was
approximately 77% compared to 33% for the overall
hepatitis C cohort during 2014-2017.(42) Our analysis was limited, therefore, in that it was (unintentionally) heavily weighted with survey respondents who
received DAAs, which may have hampered our ability
to rely on survey responses to understand barriers to
treatment in the overall survey-eligible cohort of nearly
14,000 patients. However, it is remarkable that the
presence of psychosocial impairments was significantly
more frequent among respondents who did not initiate
DAAs compared with those who did, given that only
23% of respondents did not initiate DAAs. It is possible that these impairment differences were even more
pronounced among the 60% of patients who did not
respond to the survey. Also, given that only one sixth
of our respondents were Medicaid recipients, it could
be reasoned that treatment populations consisting of
mostly patients with Medicaid might demonstrate even
more pervasive degrees of psychosocial impairment.
Nonetheless, for some variables, such as recent
injection drug use, the number of respondents who
reported recent use was low (n = 11), so differences
between treated and untreated respondents, although
statistically significant, may have been underpowered to make definitive assessments. Our study was
also limited by the absence of provider perspectives
about barriers to DAA initiation, which reduced our
capacity to explicate fully the associations between
psychosocial impediments and initiation of treatment.
For example, it is unknown whether patients who
were severely depressed were less likely to seek treatment in the first place, if they were depressed because
they had sought treatment but were denied it, or if
they were offered treatment but declined to follow
through with the process. We did, however, examine
specific access to care issues among respondents who
did not initiate DAA treatment. Almost half of these
patients were not referred or were unsure whether
they had been referred to specialty care. Of those who
had been referred but not treated, approximately one
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third reported that either they were told they were
“not sick enough” for treatment or were not told at
all why they were not offered DAAs. Only small proportions of nontreated respondents explicitly noted
an inability to pay for referral visits and medications,
that they had been denied insurance coverage for
them, or reported having more pressing medical or
situational concerns. However, it was probable that
some patients were not referred or offered treatment
because of provider awareness of the futile nature of
preauthorization constraints or because of “other reasons” not acknowledged by respondents; therefore, the
low frequency of survey-reported financial and insurance barriers or of unacknowledged issues regarding
nonadherence or substance use/mental health problems likely underestimated the true effect of these
factors. For example, respondents with Medicaid and
Medicare (without supplemental coverage) were less
likely to receive DAAs in the univariable analysis.
In Michigan, the location of our principal study site,
Medicaid coverage for DAAs was delayed and fibrosis restrictions remained in place long thereafter.(47)
A similar situation existed in Pennsylvania where
another study site was located. The situation is less
clear with our Medicare respondents, although there
have been reports of difficulties with receipt of DAAs
among Medicare recipients, particularly those lacking
Part D coverage or with Part D coverage subject to
high copays, or with Medicare/Medicaid dual coverage subject to state-specific Medicaid drug coverage
rules.(48) Unfortunately, not all our study sites (each
in a different state) collected information on Part D
coverage, so we were not able to discern whether or to
what degree this might be an issue.
Understanding such complex issues might be difficult to unravel with respect to causation, yet our
identification of several adverse behavioral, psychological, and social qualities associated with noninitiation of DAAs among these patients in care suggests
the presence of additional treatment barriers to be
addressed by clinicians and programs dedicated to
reducing the morbidity and mortality burden of
hepatitis C and ultimately to its elimination as a
public health threat.
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